Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
PLoS One ; 9(8): e104917, 2014.
Article in English | MEDLINE | ID: mdl-25111507

ABSTRACT

OBJECTIVES: To study the baseline PSA profile and determine the factors influencing the PSA levels within a multiethnic Asian setting. MATERIALS AND METHODS: We conducted a cross-sectional study of 1054 men with no clinical evidence of prostate cancer, prostate surgery or 5α-reductase inhibitor treatment of known prostate conditions. The serum PSA concentration of each subject was assayed. Potential factors associated with PSA level including age, ethnicity, height, weight, family history of prostate cancer, lower urinary tract voiding symptoms (LUTS), prostate volume and digital rectal examination (DRE) were evaluated using univariable and multivariable analysis. RESULTS: There were 38 men (3.6%) found to have a PSA level above 4 ng/ml and 1016 (96.4%) with a healthy PSA (≤4 ng/ml). The median PSA level of Malay, Chinese and Indian men was 1.00 ng/ml, 1.16 ng/ml and 0.83 ng/ml, respectively. Indians had a relatively lower median PSA level and prostate volume than Malays and Chinese, who shared a comparable median PSA value across all 10-years age groups. The PSA density was fairly similar amongst all ethnicities. Further analysis showed that ethnicity, weight and prostate volume were independent factors associated with age specific PSA level in the multivariable analysis (p<0.05). CONCLUSION: These findings support the concept that the baseline PSA level varies between different ethnicities across all age groups. In addition to age and prostate volume, ethnicity may also need to be taken into account when investigating serum PSA concentrations in the multiethnic Asian population.


Subject(s)
Prostate-Specific Antigen/blood , Prostate/physiology , Adult , Age Factors , Aged , Asian People , Cross-Sectional Studies , Digital Rectal Examination , Humans , Male , Middle Aged , Organ Size/physiology , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Reference Values , Urination/physiology
2.
Urology ; 81(4): 904-7, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23537760

ABSTRACT

OBJECTIVE: To describe a novel technique for localizing small testicular mass during testicular-sparing surgery (TSS). METHODS AND RESULTS: A 20-year-old man presented with bilateral testicular masses. Both alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (BHCG) levels were raised. Clinical and imaging studies revealed a 2.7 cm and 0.7 cm mass in the right and left testis, respectively. No metastatic disease was detected on staging scans. Right inguinal total orchiectomy was performed. For the left testis, the inguinal approach was used to deliver the testis to the surgical wound. Vascular clamping and cooling of the testis were performed. A hook wire (Ghiatas Beaded Breast Localization Wire, 20G) was then inserted through the small testicular tumor with the aid of on-table ultrasound imaging. Testicular-sparing surgery (TSS) was easily performed with the aid of the hook wire. Postoperative recovery was uneventful. The histology report revealed a mixed germ cell tumor with clear margin. Tumor markers returned to normal after surgery. Serum testosterone level was also within normal range. Follow-up ultrasound scan showed a viable left testis with normal vascularity. CONCLUSION: Hook wire localization of a small testicular mass under ultrasound guidance is an easy-to-perform technique that facilitates TSS in selected patients. This technique allows TSS to be performed in a more controlled and confident manner.


Subject(s)
Neoplasms, Germ Cell and Embryonal/surgery , Testicular Neoplasms/surgery , Testis/surgery , Urologic Surgical Procedures, Male/instrumentation , Humans , Male , Neoplasms, Germ Cell and Embryonal/diagnostic imaging , Orchiectomy , Testicular Neoplasms/diagnostic imaging , Testis/diagnostic imaging , Ultrasonography , Young Adult
3.
Drugs ; 66(18): 2339-55, 2006.
Article in English | MEDLINE | ID: mdl-17181376

ABSTRACT

Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.


Subject(s)
Androgens/therapeutic use , Dopamine Agonists/therapeutic use , Erectile Dysfunction/drug therapy , Hormone Replacement Therapy , Phosphodiesterase Inhibitors/therapeutic use , Vasodilator Agents/therapeutic use , Constriction , Cost of Illness , Erectile Dysfunction/diagnosis , Erectile Dysfunction/surgery , Erectile Dysfunction/therapy , Exercise Therapy , Health Care Costs , Humans , Incidence , Male , Medical History Taking , Pelvic Floor , Practice Guidelines as Topic , Psychotherapy/methods , Referral and Consultation , Severity of Illness Index , Surveys and Questionnaires , Urologic Surgical Procedures, Male , Vacuum
4.
BJU Int ; 97(6): 1199-201, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16566814

ABSTRACT

OBJECTIVE: To evaluate a series of repeat transurethral resections (TURs) of tumour in patients with T1 bladder cancer, usually used to ensure a complete resection and to exclude the possibility muscle-invasive disease. PATIENTS AND METHODS: In all, 136 consecutive patients had a second TUR because of a histopathological diagnosis of T1 transitional cell carcinoma (TCC) after their initial TUR. Of the 136 patients, 101 were first presentations and 35 had recurrent tumours. The second TUR was done 4-6 weeks later. The evaluation included the presence of previously undetected residual tumour, changes to histopathological staging/grading, and tumour location. RESULTS: In all, 71 patients (52%) had residual disease according to findings from specimens obtained during the second TUR. The staging was: no tumour, 65 (48%); Ta, 11 (8%); T1, 32 (24%); Tis, 15 (11%); and > or = T2, 13 (10%). Histopathological changes that worsened the prognosis (>T1 and or concomitant Tis) were found in 21% of patients. Residual malignant tissue was found in the same location as the first TUR in 86% of the patients, and at different locations in 14%. Overall, 28 patients (21% of the original 136) had a radical cystectomy as a consequence of the second TUR findings. CONCLUSIONS: A routine second TUR should be advised in patients with T1 TCC of the bladder, to achieve a more complete tumour resection and to identify patients who should have a prompt cystectomy.


Subject(s)
Carcinoma, Transitional Cell/surgery , Cystectomy/methods , Neoplasm Invasiveness/prevention & control , Urinary Bladder Neoplasms/surgery , Carcinoma, Transitional Cell/pathology , Humans , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Reoperation , Treatment Outcome , Urethra , Urinary Bladder Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...